Market Analysis and Insights: Europe and United States Prothrombin Complex Concentrate (PCC) Drug Market
Due to the COVID-19 pandemic, the Europe and United States Prothrombin Complex Concentrate (PCC) Drug market size is estimated to be worth US$ 674.7 million in 2022 and is forecast to a readjusted size of US$ 1314.68 million by 2028 with a CAGR of 11.76% during the review period. Fully considering the economic change by this health crisis, Beriplex accounting for 68.2% of the Prothrombin Complex Concentrate (PCC) Drug Europe and United States market in 2021, is projected to value US$ 887 million by 2028, growing at a revised 11.52% CAGR in the post-COVID-19 period.
In Europe and United States, the key manufacturers of Prothrombin Complex Concentrate (PCC) Drug include CSL Behring, Grifols, Octapharma, Prothya Biosolutions, and Takeda. In 2021, the Europe and United States top five players have a share approximately 98% in terms of revenue.
Europe and United States Prothrombin Complex Concentrate (PCC) Drug Scope and Segment
Prothrombin Complex Concentrate (PCC) Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the Europe and United States Prothrombin Complex Concentrate (PCC) Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type, and by Application for the period 2017-2028.
By Company
CSL Behring
Grifols
Octapharma
Prothya Biosolutions
Takeda
Segment by Type
Beriplex
Profilnine
Octaplex
Prothromplex
Cofact
Other
Segment by Application
Hemophilia B
Acquired Coagulation Factor Deficiency
Others
Segment by Country/Region
United States
Germany
France
UK
Italy
Spain
Netherland
Other Countries
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook